argenex SE (NASDAQ:ARGX) Stock Rated “Moderate Buy” by Sell-Side Brokerages

argenex SE (NASDAQ:ARGX) has been given a consensus recommendation of “Moderate Buy” by the twenty-eight analysts that are covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation, twenty-one have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $1,158.76.

Several equities research analysts have weighed in on the company. Wells Fargo & Company lowered their target price on argenex from $1,356.00 to $1,336.00 and set an “overweight” rating for the company in a report on Friday, October 23rd. Citizens Jmp raised their price target on argenex from $932.00 to $1,200.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 18th. Truist Financial lifted their price objective on argenex from $1,030.00 to $1,095.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Oppenheimer lowered their price objective on shares of argenex from $1,100.00 to $1,038.00 and set an “outperform” rating for the company in a research note on Monday, October 12th. Finally, Citigroup dropped their target price on shares of argenex from $1,301.00 to $1,232.00 and set a “buy” rating on the stock in a report on Tuesday, October 27th.

Institutional Investors Weigh In On argenex

Several hedge funds have recently modified their holdings of the business. Eastern Bank acquired a new position in argenex during the 2nd quarter valued at about $32,000. Whipplewood Advisors LLC purchased a new stake in argenex in the first quarter valued at about $28,000. Axiom Investment Management LLC purchased a new stake in argenex in the first quarter valued at about $50,000. Richardson Financial Services Inc. acquired a new stake in argenex in the third quarter worth about $66,000. Finally, Mather Group LLC. boosted its holdings in argenex by 19.1% in the third quarter. Mather Group LLC. now owns 81 shares of the company’s stock worth $78,000 after acquiring an additional 13 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Stock Performance

Shares of NASDAQ:ARGX opened at $874.97 on Thursday. The firm’s 50 day simple moving average is $940.31 and its 200-day simple moving average is $855.14. argenex has a one year low of $661.85 and a one year high of $1,072.75. The firm has a market cap of $55.03 billion, a PE ratio of 30.53, a price-to-earnings-growth ratio of 0.82 and a beta of 0.44.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.44 by $0.36. argenex had a return on equity of 47.70% and a net margin of 31.66%. The firm had revenue of $1.75 billion during the quarter. Equities research analysts predict that argenex will post 28.63 EPS for the current fiscal year.

argenex Company Profile

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.